Background
==========

Li-Fraumeni syndrome (LFS) is a rare disorder that considerably increases the risk of developing several types of cancer, particularly in children and young adults. The first observations were described by Li and Fraumeni in 1969 \[[@B1]\]. LFS is inherited in an autosomal dominant pattern with the frequent occurrence of soft tissue/bone sarcoma, breast cancer, leukemia, brain tumors and other cancers (melanoma, colon cancer, pancreatic cancer, adrenocortical carcinoma) \[[@B1],[@B2]\]. Since then, several reports of affected families have contributed to a more precise definition of the Li Fraumeni syndrome \[[@B3]\].

Germ-line *TP53*gene mutations are mainly reported in LFS and approximately 250 distinct germ-line *TP53*mutations have been described in the literature \[[@B4]\]. A *TP53*mutation database has been established <http://www-p53.iarc.fr/>\[[@B5]\]. Mutations in the *CHEK2*gene have also been reported in a few LFS and Li Fraumeni-like syndrome (LFL) families \[[@B6]-[@B8]\]. Wild-type p53 was identified as the first tumor suppressor gene. It is at the crossroads of the network of signaling pathways involved in the elimination and inhibition of abnormal cell proliferation designed to prevent neoplastic development \[[@B9],[@B10]\]. Many transcriptional targets of wild-type p53 have been implicated: (i) in cell cycle inhibition by maintaining cells in the G2 cell cycle arrest, for example, the cyclin-dependent kinase inhibitor p21^Waf1^, 14-3-3sigma (σ); (ii) in the regulation of apoptosis through the induction of pro-apoptotic proteins such as Bax, Apaf 1, PUMA, p53AIP1, PIDD and NOXA; (iii) in DNA repair; (iv) in angiogenesis and in metastasis inhibition \[[@B11]-[@B13]\]. p53 gene inactivation is essentially due to small mutations which lead to either the expression of a mutant protein (90% of cases) or the absence of protein expression (10% of cases). Here, we attempted to assess the incidence of radio-induced malignancies in a prospective cohort of families with germ-line p53 mutations, focusing on breast cancer occurring as the first malignancy.

Methods
=======

We conducted a search of the genetic screening database at the Institut Gustave Roussy (*Villejuif)*for \"female AND breast cancer AND mutation of TP53\" from 1997 to 2007. Clinical, pathological, and treatment characteristics were assessed and the analysis was performed in February 2010. A loco-regional relapse was defined as an ipsilateral relapse in either the breast or lymph node-bearing areas (axillary, internal mammary, supra-clavicular) or both occurring since the date of the diagnosis. Contralateral breast cancer was either ductal carcinoma *in situ*(DCIS) or invasive carcinoma. Distant disease was defined as breast carcinoma recurrences that were not in the contralateral breast nor in loco-regional areas. Second primaries were recorded in the database.

Results
=======

Among 47 families with either LFS or LFL syndrome, eight patients were recorded as having a breast cancer as the first malignancy. The median follow-up was 6 years \[2-13\]. Median age was 30 years \[22-48\]. Among those 8 patients, 6 had received loco-regional radiation therapy. After a median follow-up of 6 years since the initial diagnosis \[2-13\], 3 ipsilateral breast relapses and 4 contralateral breast cancers had occurred and 2 radio-induced cancers (one chest wall angiosarcoma and one breast histiocytofibrosarcoma). One papillary thyroid carcinoma had also developed inside the radiation field, which was considered as a new primary rather than a radio-induced malignancy because of the two years of latency. Two other primaries had also occurred: a buttock liposarcoma and an ethmoidal leiomyosarcoma. Two patients had developed metastases from the primary breast carcinoma and one patient had died of metastatic disease.

Patient 1
---------

A 27 year-old woman with a familial history of LFS had presented with a 35 mm DCIS of the left breast that had been treated by a radical mastectomy and axillary clearance in 1999. She had no evidence of a relapse.

Patient 2
---------

A 32 year-old woman with a familial history of LFS had presented with a right breast cancer (Scarff and Bloom and Richardson (SBR) grade 1 invasive ductal carcinoma (IDC), pT1N0, ER+, PR+, HER2-) that had been treated by a radical mastectomy and Tamoxifen in 2007. One year after the initiation of Tamoxifen, a contralateral breast cancer (CBC) had occurred (DCIS) that had been treated by a radical mastectomy.

Patient 3
---------

A 22 year-old woman with a familial history of multiple breast cancers had presented in 2005 with an IDC of the right breast (cT2N1, ER+, PR+, HER2+) that had been treated with neo-adjuvant chemotherapy and traztuzumab. A radical mastectomy and an axillary dissection(1N+/25) had been performed followed by loco-regional radiotherapy to the chest wall, internal mammary and supraclavicular nodes, endocrine therapy and a prophylactic contralateral mastectomy.

Patient 4
---------

A 32 year-old woman without any familial history of cancer had presented with an IDC of the right breast (SBR grade 2 T1N1 ER+, PR+, Her2+). She had been treated by a radical mastectomy followed by chemotherapy with traztuzumab, loco-regional irradiation (chest wall, internal mammary and supraclavicular nodes) and Tamoxifen. Before completion of traztuzumab, i.e. 8 months after completion of radiotherapy, a CBC had been diagnosed (left axillary IDC, ER+, PR+, HER2+) that had been treated by a lumpectomy including a sentinel lymph node biopsy and chemotherapy with traztuzumab. The p53 mutation had been diagnosed during chemotherapy. Postoperative radiotherapy had therefore been cancelled and replaced by a mastectomy.

Patient 5
---------

A 22 year-old woman without any familial history of cancer had presented with a right breast phyllodes tumor in 1997. Conservative breast surgery had been performed followed by adjuvant radiotherapy delivered to the whole breast. In 2001, she had developed a buttock liposarcoma and then a CBC (SBR grade 2 IDC) in 2004 that had been treated by conservative surgery followed by radiotherapy to the breast, internal mammary and supraclavicular nodes. An ipsilateral breast cancer (IBC) had occurred in 2008, (\"in-field relapse\": a 50 mm, ER-, PR-, Her2+ mucinous carcinoma ). It had been treated by a radical mastectomy and with traztuzumab. Due to the occurrence of multiple malignancies at a very young age in this patient, she had received genetic counseling and a p53 mutation had been diagnosed. At the time of the analysis (Feb. 2010), she developed an ipsilateral chest wall angiosarcoma which is currently being treated with chemotherapy.

Patient 6
---------

A 29 year-old woman with a familial history of multiple cancers had undergone conservative surgery of the right breast for an IDC (SBR grade 2 T1N1, ER+, PR+, HER2-) in 1998. She had received adjuvant chemotherapy and radiotherapy. An ipsilateral, multicentric breast recurrence (IDC) had developed 10 years later (an in-field relapse of the same histologic type) and had been treated by a radical mastectomy and endocrine therapy. A TP53 mutation had been diagnosed in 2008. At the time of the analysis (Feb. 2010), a contralateral axillary recurrence was diagnosed and treated with chemotherapy.

Patient 7
---------

A 48 year-old female had presented in 2005 with a right breast cancer (IDC) with axillary lymph node involvement and a concomitant grade 2 malignant histiocytofibroma of the left thigh measuring 8 cm. She had a familial history of cancer (2 brothers with rhabdomyosarcoma, and cancers in both parents). She had received five cycles of adriamycin and ifosfamide (AI), 9 cycles of weekly paclitaxel and had undergone a mastectomy with axillary clearance for the IDC (SBR grade 3 ER+, PR+, HER2-) measuring 120 mm with multiple vascular involvement (VI) and 9N+/16. She had received radiotherapy to the chest wall, internal mammary and supraclavicular nodes and endocrine therapy. She had undergone surgery for the malignant histiocytofibroma of the thigh after the 5 cycles of AI.

In August 2007, she had undergone a thyroidectomy and bilateral neck and superior mediastinal lymph node dissection for a papillary carcinoma with VI, 10N+, followed by radioactive iodine therapy. In April 2008, she had developed a liver metastasis and had been treated with 3 lines of chemotherapy. She had progressive disease at the time of the analysis (Feb 2010).

Patient 8
---------

A 39 year-old female diagnosed with a DCIS of the left breast had undergone a lumpectomy and had received postoperative radiotherapy and tamoxifen. In 2004, she had developed a local relapse that had been treated by a mastectomy and axillary clearance. Two tumors had been discovered: one grade 2 histiocytofibrosarcoma and 6N+ exhibiting IDC (ER+, PR+, HER2-). She had received adjuvant chemotherapy, radiotherapy to the chest wall, internal mammary and supraclavicular nodes and then endocrine therapy. In 2006, she had developed a grade 2 ethmoidal leiomyosarcoma that had been treated by surgery and radiotherapy. In December 2006, she had presented with a left infracapsular mass which had been diagnosed as metastasis from IDC and had been treated with chemotherapy. She had developed cerebral metastasis in September 2007 and pleural metastasis in December of the same year. She had died at the end of 2008 of disease progression. Her 18 year-old daughter has 2 sarcomas.

Genomic analysis
================

TP53 analysis
-------------

The 11 exons of TP53 and intron-exon boundaries were thoroughly analyzed by direct sequencing after genomic DNA amplification. Genomic rearrangements were sought by Quantitative Multiplex Polymerase chain reaction of Short Fragments (QMPSF), as described elsewhere \[[@B14]\].

We screened the mutations on the IARC website <http://www-p53.iarc.fr>. Table [1](#T1){ref-type="table"} lists the type of germ-line p53 mutation for each patient. The majority of the mutations were missense mutations resulting in abnormal protein function. Patients 1 and 8 had a splicing mutation. The splicing mutation in patient 1 has already been described as a germ-line mutation in 8 LFS families and the mutation in patient 8, which induces buried DNA-binding function, has already been described in 2 LFS families.

###### 

Patient characteristics, outcome and genetic information

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                 1                     2                 3                 4              5                     6                 7                 8
  ------------------------------ --------------------- ----------------- ----------------- -------------- --------------------- ----------------- ----------------- ----------------
  Age                            27                    32                22                32             22                    29                48                39

                                                                                                                                                                    

  Histology                      DCIS                  IDC and DCIS      IDC               IDC            Phyllodes sarcoma     IDC               IDC               DCIS

                                                                                                                                                                    

  Grade                          NA                    1                 NA                2              NA                    2                 3                 NA

                                                                                                                                                                    

  Hormonal receptor              UN                    pos               pos               pos            NA                    pos               pos               pos

                                                                                                                                                                    

  HER2 overexpression            NA                    neg               pos               pos            NA                    neg               neg               NA

                                                                                                                                                                    

  TNM                            TisN0M0               T1N0M0            T2N1M0            T1N1M0         TxN0M0                T1N1M0            T4N1M0            TisN0M0

                                                                                                                                                                    

  Adjuvant Radiotherapy          No                    No                Yes               Yes            Yes                   Yes               Yes               Yes

                                                                                                                                                                    

  Local relapse                  No                    No                No                No             Yes                   Yes               No                Yes

                                                                                                                                                                    

  Contralateral breast cancer    No                    Yes               No                Yes            Yes                   Yes               No                No

                                                                                                                                                                    

  Radio induced tumors           No                    No                No                No             Yes                   No                \*                Yes

                                                                                                                                                                    

  New primary outside RT field   No                    No                No                No             Yes                   No                No                Yes

                                                                                                                                                                    

  Codon\                         c.375G \> C exon 4\   c.844C \> T\      c.742C \> T\      c.467G \> A\   c.724T \> C exon 7\   c.542G \> A\      c.524G \> A\      c.673-2A \> G\
  Mutation                       splice site           exon 8 missense   exon 7 missense   exon 5\        missense              exon 5 missense   exon 5 missense   intron 6\
                                                                                           missense                                                                 splice site
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DCIS: ductal carcinoma in situ; IDC: invasive ductal carcinoma; UN unknown; NA: non applicable; \* in field tumor with atypical histology

Discussion
==========

To our knowledge, this is the first report on breast cancer as the first tumor in LFS, without any previous cytotoxic therapy. A large retrospective cohort study assessed the outcomes of long-term survivors after cancer treatments in childhood. The results were alarming because they suggested that chemotherapy and ionizing radiation exposure increased the incidence of second malignancies. More specifically, radiation exposure among TP53 mutation carriers seemed to increase second cancers \[[@B15]\]. Other small cohort studies have suggested a similar outcome \[[@B16]-[@B19]\].

No specific clinical or histological feature of breast cancer occurring as a first event has been described in other series. A young age is commonly associated with an aggressive breast cancer phenotype \[[@B20],[@B21]\]. Furthermore, a young age implied breast cancer mutations, such as BRCA mutations. In BRCA1 mutation carriers, breast cancers mostly exhibited a basal-like molecular phenotype \[[@B22]\].

Besides the histological characteristics of breast cancers associated with a young age, a young age has also been reported to be a poor prognostic factor for distant metastases \[[@B23],[@B24]\]. Nonetheless, in the present study with a median follow-up of 6 years, only 2/8 patients had developed distant metastases. Indeed, our patients had mostly developed either local recurrences or contralateral breast cancer.

In an overall population of patients treated for a breast cancer, the risk of loco-regional relapse after breast surgery and postoperative radiotherapy is commonly reported to be 1% per year. A young age is the main prognostic factor for loco-regional relapses with a first peak before the first 2-3 years after the completion of treatment followed by a decreasing risk over time \[[@B20]\]. Even though the cohort under study was small, an ipsilateral breast relapse (\"in-field relapse\") had occurred in 3/8 patients (in 2, ten years after the initial diagnosis). In addition, CBC had occurred in 4/8 patients but one had undergone a prophylactic contralateral mastectomy.

Radio-induced cancers are usually a very rare event arising 10 years after irradiation with an incidence of less than 2 ‰ \[[@B25]\]. In the present cohort of LFS, a chest wall angiosarcoma, a malignant histiocytofibroma and a papillary thyroid carcinoma had developed inside the irradiated volumes in 3/8 patients.

Experimental data highlighted the role of ionizing radiation stress in human cells harboring heterozygous germ-line p53 mutations, leading to a defective cell cycle arrest in G1/S and/or a lesser apoptotic response of lymphocytes \[[@B26]\]. All these cellular features may promote radiosensitization and thus carcinogenesis \[[@B26]\]. In addition to these *in vitro*results, *in vivo*studies showed that ionizing radiation accelerated the emergence of solid tumors in Trp53 heterozygous null mice \[[@B27]\]. To reinforce experimental data, a few, albeit, very small retrospective cohort studies have reported a higher risk of developing a radiation-induced malignancy among *TP53*mutation carriers \[[@B16]-[@B19]\].

The events described here are probably the result of the sum of the effects of the genetic background on both the risk of new primaries, especially within the breast, and the risk of radiation-induced carcinogenesis. Recent data highlighted the importance of a familial history of cancer or multiple primary tumours (6/8 patients in our cohort) \[[@B2],[@B28]\]. Thus, we strongly believe that patients with early onset breast cancer should be tested for *TP53*mutation according to updated Chompret criteria \[[@B28]\].

Conclusion
==========

If a germ-line mutation is detected, we recommend that it be taken into account for decision-making concerning local treatment: 1. Adjuvant radiation therapy for localized breast cancer should be extensively discussed and prohibited whenever the risk/benefit ratio is doubtful. 2. Both a mastectomy of the cancer-bearing breast and a contralateral prophylactic mastectomy (with immediate reconstruction, as frequently as possible) should be advised and discussed with the patient, as is the case for BRCA1/2 mutation carriers, with the additional advantage of potentially avoiding radiation therapy if conservative treatment is avoided.
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